• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Am Coll Cardiol . International Prospective Registry of Acute Coronary Syndromes in Patients With COVID-19

tetano

Editor, Senior Moderator
J Am Coll Cardiol


. 2021 May 25;77(20):2466-2476.
doi: 10.1016/j.jacc.2021.03.309.
International Prospective Registry of Acute Coronary Syndromes in Patients With COVID-19


Thomas A Kite[SUP] 1 [/SUP], Peter F Ludman[SUP] 2 [/SUP], Chris P Gale[SUP] 3 [/SUP], Jianhua Wu[SUP] 3 [/SUP], Adriano Caixeta[SUP] 4 [/SUP], Jacques Mansourati[SUP] 5 [/SUP], Manel Sabate[SUP] 6 [/SUP], Pilar Jimenez-Quevedo[SUP] 7 [/SUP], Luciano Candilio[SUP] 8 [/SUP], Parham Sadeghipour[SUP] 9 [/SUP], Angel M Iniesta[SUP] 10 [/SUP], Stephen P Hoole[SUP] 11 [/SUP], Nick Palmer[SUP] 12 [/SUP], Albert Ariza-Sol?[SUP] 13 [/SUP], Alim Namitokov[SUP] 14 [/SUP], Hector H Escutia-Cuevas[SUP] 15 [/SUP], Flavien Vincent[SUP] 16 [/SUP], Otilia Tica[SUP] 17 [/SUP], Mzee Ngunga[SUP] 18 [/SUP], Imad Meray[SUP] 19 [/SUP], Andrew Morrow[SUP] 20 [/SUP], Md Minhaj Arefin[SUP] 21 [/SUP], Steven Lindsay[SUP] 22 [/SUP], Ghada Kazamel[SUP] 23 [/SUP], Vinoda Sharma[SUP] 24 [/SUP], Aly Saad[SUP] 25 [/SUP], Gianfranco Sinagra[SUP] 26 [/SUP], Federico Ariel Sanchez[SUP] 27 [/SUP], Marek Roik[SUP] 28 [/SUP], Stefano Savonitto[SUP] 29 [/SUP], Marija Vavlukis[SUP] 30 [/SUP], Shankar Sangaraju[SUP] 31 [/SUP], Iqbal S Malik[SUP] 32 [/SUP], Sharon Kean[SUP] 33 [/SUP], Nick Curzen[SUP] 34 [/SUP], Colin Berry[SUP] 35 [/SUP], Gregg W Stone[SUP] 36 [/SUP], Bernard J Gersh[SUP] 37 [/SUP], Anthony H Gershlick[SUP] 38 [/SUP], International COVID-ACS Registry Investigators



Affiliations

Abstract

Background: Published data suggest worse outcomes in acute coronary syndrome (ACS) patients and concurrent coronavirus disease 2019 (COVID-19) infection. Mechanisms remain unclear.
Objectives: The purpose of this study was to report the demographics, angiographic findings, and in-hospital outcomes of COVID-19 ACS patients and compare these with pre-COVID-19 cohorts.
Methods: From March 1, 2020 to July 31, 2020, data from 55 international centers were entered into a prospective, COVID-ACS Registry. Patients were COVID-19 positive (or had a high index of clinical suspicion) and underwent invasive coronary angiography for suspected ACS. Outcomes were in-hospital major cardiovascular events (all-cause mortality, re-myocardial infarction, heart failure, stroke, unplanned revascularization, or stent thrombosis). Results were compared with national pre-COVID-19 databases (MINAP [Myocardial Ischaemia National Audit Project] 2019 and BCIS [British Cardiovascular Intervention Society] 2018 to 2019).
Results: In 144 ST-segment elevation myocardial infarction (STEMI) and 121 non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients, symptom-to-admission times were significantly prolonged (COVID-STEMI vs. BCIS: median 339.0 min vs. 173.0 min; p < 0.001; COVID NSTE-ACS vs. MINAP: 417.0 min vs. 295.0 min; p = 0.012). Mortality in COVID-ACS patients was significantly higher than BCIS/MINAP control subjects in both subgroups (COVID-STEMI: 22.9% vs. 5.7%; p < 0.001; COVID NSTE-ACS: 6.6% vs. 1.2%; p < 0.001), which remained following multivariate propensity analysis adjusting for comorbidities (STEMI subgroup odds ratio: 3.33 [95% confidence interval: 2.04 to 5.42]). Cardiogenic shock occurred in 20.1% of COVID-STEMI patients versus 8.7% of BCIS patients (p < 0.001).
Conclusions: In this multicenter international registry, COVID-19-positive ACS patients presented later and had increased in-hospital mortality compared with a pre-COVID-19 ACS population. Excessive rates of and mortality from cardiogenic shock were major contributors to the worse outcomes in COVID-19 positive STEMI patients.

Keywords: COVID-19; ST-segment elevation myocardial infarction; acute coronary syndrome; cardiogenic shock; non?ST-segment elevation myocardial infarction.
 
Back
Top Bottom